Disease · MONDO_0002679

cerebral infarction

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cerebral infarction. Diseases, record MONDO_0002679. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002679

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cerebral infarction; Open Targets
Open Targets ID: MONDO_0002679; Open Targets
Other names: CVA - cerebral infarction, brain infarction of telencephalon, cerebral infarct, cerebral ischemia, infarction, cerebral, telencephalon brain infarction; Open Targets
Disease Ontology: DOID:3526; Disease Ontology
MeSH: D002544; MeSH
NCI Thesaurus: C50486; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 24 drugs, from PMDA; Open Targets

Drugs24

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ASPIRIN	CHEMBL25	Small molecule	Approval	PMDA	2	0	0	Drugs and targets
LANSOPRAZOLE	CHEMBL480	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
VONOPRAZAN FUMARATE	CHEMBL2064032	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
CLOPIDOGREL	CHEMBL1771	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NERINETIDE	CHEMBL502630	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM LACTATE	CHEMBL1357	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TICAGRELOR	CHEMBL398435	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
HYDROXYETHYL STARCH 130/0.4	CHEMBL2108701		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MINOCYCLINE	CHEMBL1434	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 24

See all 24 drugs

Targets24

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ATP4A	Potassium-transporting ATPase	2	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	2	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/496	Drugs and targets
P2RY12	P2Y purinoceptor 12	2	Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/64805	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/152	Drugs and targets
AVPR1A	Vasopressin receptor	1	Vasopressin receptor agonist	Unknown	https://conductscience.org/library/genes/552	Drugs and targets
AVPR1B	Vasopressin receptor	1	Vasopressin receptor agonist	Unknown	https://conductscience.org/library/genes/553	Drugs and targets
AVPR2	Vasopressin receptor	1	Vasopressin receptor agonist	Unknown	https://conductscience.org/library/genes/554	Drugs and targets
F10	Coagulation factor X	1	Coagulation factor X inhibitor	Unknown	https://conductscience.org/library/genes/2159	Drugs and targets

1 to 10 of 24

See all 24 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00795366	Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients	Not applicable	96	2014-12-12	Traumatic Brain Injury	VASOPRESSIN	Its record names the disease	ClinicalTrials.gov
NCT06853535	Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE	Phase 3	5,138		Acute Ischemic Stroke, Clopidogrel Resistance	CLOPIDOGREL, TICAGRELOR	Its record names the disease	ClinicalTrials.gov
NCT04010955	Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)		1,200		Acute Ischemic Stroke, Atrial Fibrillation, Extracranial Atherosclerosis, Intracranial Atherosclerosis, Coronary Artery Atherosclerosis, Peripheral Artery Stenosis, Anticoagulant, Antiplatelet	EDOXABAN	Its record names the disease	ClinicalTrials.gov
NCT02315443	Field Randomization of Nerinetide (NA-1) Therapy in Early Responders	Phase 3	532		Acute Cerebral Ischemia	NERINETIDE	Its record names the disease	ClinicalTrials.gov
NCT01192581	Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection as Adjunctive Therapy in Subjects With Internal Carotid Artery Hypoperfusion	Phase 2	120		Brain Hypoperfusion	HYDROXYETHYL STARCH 130/0.4	Its record names the disease	ClinicalTrials.gov
NCT03451903	Which Factors Influence the Duration and the Success of Mechanical Thrombectomy During the Acute Phase of Cerebral Infarction?		106		Acute Stroke	ALTEPLASE	Its record names the disease	ClinicalTrials.gov
NCT05857046	Cerebroprotective Effect of Melatonin in Stroke	Phase 3	100		Stroke, Acute Ischemic, Strokes Thrombotic	MELATONIN	Its record names the disease	ClinicalTrials.gov
NCT02258204	Ketamine for Thrombolysis in Acute Ischemic Stroke	Phase 1/2	50		Stroke	KETAMINE	Its record names the disease	ClinicalTrials.gov
NCT04876638	Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)	Phase 2	20		Aneurysm, Ruptured, Vasospasm, Intracranial, Delayed Cerebral Ischemia, Blood Brain Barrier Defect	MINOCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT01687868	Evaluation of Efficacy and Safety of General Anesthesia Using Dexmedetomidine With Sevoflurane in Patients Undergoing Arthroscopic Shoulder Surgery: Preliminary Study	Not applicable	19		Arthroscopic Shoulder Surgery in the Beach-chair Position	DEXMEDETOMIDINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
AVP, Arginine Vasopressin vs Standard Catecholamine: serious adverse events	6 of 42	6 of 54	96	NCT00795366

Source Trial comparisons

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30402285	RESULT	1	PubMed
28357821	RESULT	1	PubMed
24471697	RESULT	1	PubMed
23335971	RESULT	1	PubMed
20954243	RESULT	1	PubMed
19949909	RESULT	1	PubMed
16510383	RESULT	1	PubMed
16457083	RESULT	1	PubMed
39955120	DERIVED	1	PubMed
37548010	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002679

GET https://conductscience.org/api/diseases/v1/MONDO_0002679/drugs?page=2

API reference For AI assistants